


Neuroblastoma Research Symposium

Future treatments for high risk neuroblastoma

CRUK Cambridge Research Institute, Cambridge, 3rd December 2010
<http://www.nsoc.co.uk/symposium2010.html>



9.25: Introduction and session chair, Dr Peppy Brock (GOSH, London)

9.30: Prof. Andy Pearson (ICR, Sutton)

Therapies for high risk neuroblastoma - the past, present and future

10.00: Prof. Hermann Rohrer (MPI for Brain Research, Frankfurt)

From neurogenesis in the autonomic nervous system to neuroblastoma and back: a developmental neurobiology approach

10.30: Dr Carol Thiele (NCI, Bethesda)

Involvement of developmentally regulated tumor suppressor gene CASZ1 in neuroblastoma tumorigenesis

10.45: Prof. Rob Mairs (Beatson Laboratories, Glasgow)

Enhancing the efficacy of [¹³¹I]MIBG targeted radiotherapy of neuroblastoma

11.00: Coffee

Session chair, Dr Ramya Ramanujachar (Addenbrooke's Hospital, Cambridge)

11.30: Prof. David Kaplan (SickKids, Toronto)

Attacking neuroblastoma cancer stem cells where they reside: niche-specific approaches for relapsed metastatic disease

12.00: Prof. Ben Simons (Cavendish Laboratory and Gurdon Institute, Cambridge)

Universalities of stem cell fate in adult tissues

12.30: Dr Juliet Gray (University of Southampton)

Generating therapeutic anti-neuroblastoma immunity using immunostimulatory monoclonal antibodies

12.45: Dr John Anderson (UCL, London)

Reprogramming of T cells against GD2 for neuroblastoma adoptive immunotherapy

13.00: Lunch and posters

Session chair, Mr Keith Holmes (St George's Hospital, London)

14.00: Prof. Frank Speleman (Centre for Medical Genetics, Ghent)

Perturbed miRNA/mRNA regulatory networks in neuroblastoma: an integrated approach

14.30: Prof. Ray Stallings (RCSI, Dublin)

Prospects for miRNA mediated therapeutics for neuroblastoma

15.00: Prof. Susan Burchill (LIMM, Leeds)

Molecular monitoring of disease in children with neuroblastoma

15.15: Dr Emma Bell (NICR, Newcastle)

Retinoic acid activates a phospholipase A2/ Lipoxigenase-5/ PPAR δ cell survival pathway in neuroblastoma cells

15.30: Tea

Session chair, Dr Debbie Tweddle (NICR, Newcastle)

16.00: Prof. Gerard Evan (Department of Biochemistry, Cambridge)

Targeting Myc as a cancer therapy

16.30: Prof. John Lunec (NICR, Newcastle)

Targeting the MDM2(X)/p53/p14ARF network and determinants of response

16.45: Dr Arturo Sala (UCL, London)

E-box mediated repression of a tumour suppressor gene by a MYCN-Polycomb complex

17.00: Dr Louis Chesler (ICR, Sutton)

Transgenic models for cancer drug development in paediatric oncology

17.15: Presentation of charity funding streams, chaired by Dr Mark Gaze (CCLG)

17.30: Drinks and posters

18.30: Poster prizes

18.30-20.00: Buffet dinner



ADAM'S HATS.